These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 19435920)

  • 1. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.
    Sharma RK; Elpek KG; Yolcu ES; Schabowsky RH; Zhao H; Bandura-Morgan L; Shirwan H
    Cancer Res; 2009 May; 69(10):4319-26. PubMed ID: 19435920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.
    Sharma RK; Schabowsky RH; Srivastava AK; Elpek KG; Madireddi S; Zhao H; Zhong Z; Miller RW; Macleod KJ; Yolcu ES; Shirwan H
    Cancer Res; 2010 May; 70(10):3945-54. PubMed ID: 20406989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.
    Srivastava AK; Sharma RK; Yolcu ES; Ulker V; MacLeod K; Dinc G; Shirwan H
    PLoS One; 2012; 7(11):e48463. PubMed ID: 23144888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
    Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
    Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.
    Srivastava AK; Dinc G; Sharma RK; Yolcu ES; Zhao H; Shirwan H
    Cancer Res; 2014 Nov; 74(22):6441-51. PubMed ID: 25252915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models.
    Sharma RK; Yolcu ES; Srivastava AK; Shirwan H
    PLoS One; 2013; 8(9):e73145. PubMed ID: 24066030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
    Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
    J Immunol; 2003 Mar; 170(6):2912-22. PubMed ID: 12626542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4
    Barsoumian HB; Batra L; Shrestha P; Bowen WS; Zhao H; Egilmez NK; Gomez-Gutierrez JG; Yolcu ES; Shirwan H
    Cancer Res; 2019 Feb; 79(4):783-794. PubMed ID: 30770367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4 T-cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T-cell responses resulting in potent antitumor effects.
    Park HM; Sohn HJ; Kim YJ; Cho HI; Kim TG
    Vaccine; 2014 Dec; 32(51):6919-6926. PubMed ID: 25444817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a potent melanoma vaccine capable of stimulating CD8(+) T-cells independently of dendritic cells in a mouse model.
    Powell KL; Stephens AS; Ralph SJ
    Cancer Immunol Immunother; 2015 Jul; 64(7):861-72. PubMed ID: 25893808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
    Kudo-Saito C; Hodge JW; Kwak H; Kim-Schulze S; Schlom J; Kaufman HL
    Vaccine; 2006 Jun; 24(23):4975-86. PubMed ID: 16621183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44(+)CD62L(high) IL-7R(+) CTLs with up- and downregulation of anti- and pro-apoptosis genes.
    Wang R; Freywald A; Chen Y; Xu J; Tan X; Xiang J
    Cell Mol Immunol; 2015 Jul; 12(4):456-65. PubMed ID: 25195511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-1BB ligand activates bystander dendritic cells to enhance immunization in trans.
    Macdonald DC; Hotblack A; Akbar S; Britton G; Collins MK; Rosenberg WC
    J Immunol; 2014 Nov; 193(10):5056-64. PubMed ID: 25305314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.
    Xie Y; Wang L; Freywald A; Qureshi M; Chen Y; Xiang J
    Cell Mol Immunol; 2013 Jan; 10(1):72-7. PubMed ID: 23042534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.
    Sharma RK; Yolcu ES; Shirwan H
    Expert Rev Vaccines; 2014 Mar; 13(3):387-98. PubMed ID: 24521311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
    Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
    J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
    Ragonnaud E; Andersson AM; Pedersen AE; Laursen H; Holst PJ
    Vaccine; 2016 Apr; 34(18):2147-56. PubMed ID: 27004934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes.
    Nakagawa T; Tanino T; Onishi M; Tofukuji S; Kanazawa T; Ishioka Y; Itoh T; Kugimiya A; Katayama K; Yamamoto T; Nagira M; Ishii KJ
    Front Immunol; 2021; 12():803090. PubMed ID: 35003132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells.
    Zhao Y; Croft M
    Immunol Lett; 2012 Jan; 141(2):220-6. PubMed ID: 22037570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ.
    Madireddi S; Schabowsky RH; Srivastava AK; Sharma RK; Yolcu ES; Shirwan H
    PLoS One; 2012; 7(8):e42459. PubMed ID: 22870329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.